Dianthus Therapeutics Inc (NAS:DNTH)

$ 21.54 0.91 (4.4%) Market Cap: 632.19 Mil Enterprise Value: 231.00 Mil PE Ratio: 0 PB Ratio: 1.63 GF Score: 22/100

Dianthus Therapeutics Inc at JPMorgan Healthcare Conference Transcript
Jan 11, 2024
Magenta Therapeutics Inc Definitive Merger Agreement with Dianthus Therapeutics Inc - M&A Call Transcript
May 03, 2023
Magenta Therapeutics Inc Update on MGTA-117 - Corporate Call Transcript
Dec 13, 2022
Magenta Therapeutics Inc at Credit Suisse Healthcare Conference Transcript
Nov 08, 2022
Magenta Therapeutics Inc at JPMorgan Healthcare Conference Transcript
Jan 13, 2022
Magenta Therapeutics Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Jun 10, 2021
Magenta Therapeutics Inc MGTA-145 MM Phase 2 Clinical Trial Results Call Transcript
May 12, 2021
Magenta Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 14, 2021
Magenta Therapeutics Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Jun 11, 2020
Magenta Therapeutics, Inc. - Special Call Transcript
May 07, 2020
Magenta Therapeutics Inc at JPMorgan Healthcare Conference Transcript
Jan 15, 2020
Magenta Therapeutics Inc ASH 2019 Transcript
Dec 08, 2019
Magenta Therapeutics Inc at Goldman Sachs Global Healthcare Conference Transcript
Jun 11, 2019

Magenta Therapeutics Inc at JPMorgan Healthcare Conference Transcript

Jan 13, 2022 / 02:45PM GMT

Transcript 8-K

Daniel G. Wolle

JPMorgan Chase & Co, Research Division - Analyst

Hey, good morning, everyone. My name is Daniel Wolle. I'm one of the analysts covering SMID-cap biotech. We're continuing the 40th Annual JPM Healthcare Conference with Magenta Therapeutics. It's my pleasure to introduce CEO and President, Jason Gardner. He will be doing presentations first, followed by Q&A. (Operator Instructions)

Without further ado, Jason?

Jason Gardner

Magenta Therapeutics, Inc. - Co-Founder, CEO, President & Director

Good morning, everyone, and thank you to JPMorgan for the opportunity to present our progress and plans at Magenta towards transforming stem cell transplant as a curative therapy for patients battling blood cancers, genetic diseases and autoimmune diseases.

Magenta is a unique clinical-stage biotech, and I'm excited to share our story, especially coming off a productive year for the portfolio in 2021. We will dive into our programs and focus on the plans for the coming year.

On the next slide is our disclosure statement

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.